Product pipeline

Our investigational medicines offer simple new ways for patients and caregivers to use proven and trusted molecules.

Meaningful improvements. Innovative delivery.

Our pipeline is built around two core technologies. Our PharmFilm® technology provides precise, reliable dosing through non-invasive buccal, sublingual, and lingual film options. Complementing this is our AdrenaVerse™ platform, a proprietary prodrug technology enabling localized, sustained delivery of epinephrine across mucosal and dermal surfaces—a potential new frontier in epinephrine-based therapies.

Learn more about our core technologies

Complex molecule programs

ANAPHYLM™

(dibutepinephrine) sublingual film

Potential Indication

Type 1 allergic reactions, including anaphylaxis

Pre-Clinical Phase 1 Phase 2 Phase 3

An oral film formulation using Aquestive’s novel prodrug of epinephrine for the emergency treatment of Type 1 allergic reactions, including anaphylaxis.

Learn more

AQST-108

(epinephrine) topical gel

Potential Indication

(multiple indications)

Pre-Clinical Phase 1 Phase 2 Phase 3

A topical gel formulation of epinephrine under investigation for localized treatment of immune-related skin conditions, with initial development focused on alopecia areata.

CNS programs

LIBERVANT®

(diazepam) buccal film

Potential Indication

Acute repetitive seizures / cluster seizures

Pre-Clinical Phase 1 Phase 2 Phase 3

An oral film formulation of diazepam being developed as a rescue therapy for intermittent, stereotypic episodes of frequent seizure activity (also known as seizure clusters) in patients with epilepsy.

Learn more